Cat. No.: X24-06-ZQ080
FGFR inhibitor TKI-258, Purity ≥98%
Synonym: 405169-16-6; FGFR inhibitor; CHIR-258; CHIR258; TKI258
- MDL: MFCD10565680
- CAS Number: 405169-16-6
- Compound CID: 135398510
Product Size
10 mg; 25 mg; 50 mg; 100 mg
Properties
Description
TKI-258, soluble in DMSO and insoluble in ethanol and water, is a protein tyrosine kinase inhibitor that has shown potent biochemical activity against FGFR. It targets c-Kit, FGFR1, c-Met, CSF-1R/c-Fms, EGFR, EphA2, FGFR3, FLT3, HER2, IGF-1R, and Insulin receptor.
Molecular Formula
C21H21FN6O
Targets
c-Kit: 2 nM; FGFR1: 8 nM; c-Met: >3 μM; CSF-1R/c-Fms: 36 nM; EGFR: 2 μM; EphA2: 4 μM; FGFR3: 9 μM; FLT3: 1 μM; HER2: >10 μM; IGF-1R: >10 μM; Insulin receptor: 2 μM
Solubility
DMSO: 28 mg/mL (71.34 mM); Water: Insoluble; Ethanol: Insoluble
Identity
Confirmed by NMR/HPLC/MS.
Applications
TKI-258 is employed in the exploration of FGFR, aiding in cancer research by inhibiting FGFR, particularly in tumors with FGFR pathway dysregulation.
Related Products
Quick Links